MARKETS / NASDAQ / NMTC
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

NeuroOne Medical Technologies Corporation NMTC

14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$9.1M
▲ 163.5% vs FY2024
EPS · FY25
$-0.09
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-91.3%
Net margin · FY25
-39.6%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.1M
Revenue, FY2025 · full 14-year series below
Revenue Net income
0.00250.0050.00750.010.0-0.0201020132016202120242025
0.00250.0050.00750.010.0-0.02016202120242025

The company lost 40 cents on every revenue dollar this year.

Per share
USD -0.09
Diluted EPS, FY2025
EPS
0.40.81.2-0.09201020132016202120242025
0.40.81.2-0.092016202120242025

The company pays no cash dividend.

Profitability
-91.3%
Return on equity, FY2025
ROE
0.250.50.751-91.3%201020132016202120242025
0.250.50.751-91.3%2016202120242025
Operating margin-46.5%
Net margin-39.6%
Return on assets-44.6%

Each USD of equity lost 91 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+276.0%
+81.7%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.05B
Shares outstanding, FY2025
0.000.05201020132016202120242025
0.010.052016202120242025
Change, 5 years+2.8%
Change, 10 years

The share count grew 3% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 10.8M
total assets, end of FY2025
Total assetsUSD 10.8M
EquityUSD 7.1M
CashUSD 6.6M
Current ratio4.44×

Equity funds 66% of total assets.

History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
·
Income tax $B
·
·
·
·
−0.0
·
·
0.0
0.0
0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.09
−0.46
−0.65
−0.63
−0.93
−2.52
−0.57
−0.01
−0.01
−0.01
−0.01
0.00
−0.01
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−91.3
−348.4
−149.6
−123.8
−230.8
−3292.4
·
·
·
·
·
·
·
·
Shares out B
0.05
0.03
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
51 of 51
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed